Octreotide lar / sandostatin lar (lar=long acting release) (DrugBank: Octreotide)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 84 | サルコイドーシス | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2013-005376-17-NL (EUCTR) | 20/06/2014 | 27/02/2014 | Sandostatin therapy in sarcoidosis | Sandostatin therapy in sarcoidosis - SST in SA | Sarcoidosis MedDRA version: 16.1;Level: HLGT;Classification code 10003816;Term: Autoimmune disorders;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Sandostatin LAR INN or Proposed INN: OCTREOTIDE Other descriptive name: octreotide LAR / Sandostatin LAR (LAR=long acting release) | Erasmus Medical Center | NULL | Not Recruiting | Female: yes Male: yes | Netherlands |